GRS

TRANSLATE

MENU menu

Close close menu

GRS Blog

PAST POSTS menu

Close close menu

US FDA Publishes Guidance on Marketed Unapproved Drugs

02/10/2011

Last week, FDA published a guidance titled Marketed Unapproved Drugs—Compliance Policy Guide, which describes the agency’s enforcement priorities with regard to products that lack regulatory approval or that are not marketed in accordance with the over-the-counter (OTC) drug review. The document is a revision of the June 2006 guidance of the same name.

 

Because FDA lacks the resources to take immediate action against all illegally marketed products, it will give higher priority to enforcement actions that involve unapproved drug products in certain categories, including drugs with potential safety risks, and drugs that lack evidence of effectiveness. 

 

Author: Greer Deal, Director of Global Regulatory Services (GRS)

Past Posts...

Stem Cells and Autism
18 September 2011